BiotechTube
Vesteck

Vesteck

Wayne, United States· Est.
vesteck.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.5M

Overview

Vesteck is pioneering a disruptive endosuturing platform to address the critical unmet need of endograft fixation in aortic aneurysm repair. The company's lead device, Suture-Tight™, is in clinical development, supported by a significant NIH SBIR grant, and has demonstrated initial feasibility in human cases. With a seasoned leadership team and a prestigious global scientific advisory board, Vesteck is positioning itself to enter the large and growing market for aortic repair by potentially improving long-term outcomes and reducing healthcare costs associated with current EVAR/TEVAR procedures.

Vascular SurgeryAortic Aneurysm

Technology Platform

Endosuture Aneurysm Repair (ESAR) platform for endovascular suturing to secure aortic stent grafts.

Funding History

1
Total raised:$5.5M
Seed$5.5M

Opportunities

The Suture-Tight™ system addresses a major unmet need in EVAR/TEVAR by potentially reducing costly reinterventions, which could drive rapid adoption and favorable reimbursement.
The platform technology also offers expansion opportunities into thoracic aortic repair and other vascular applications, significantly broadening its market potential.

Risk Factors

Key risks include failure to demonstrate safety and efficacy in the pivotal clinical trial, regulatory delays or setbacks at the FDA, and challenges in achieving market adoption against established standard-of-care practices.
The company also faces competition from larger medical device firms and execution risk in scaling manufacturing and commercial operations.

Competitive Landscape

Vesteck operates in the aortic stent graft market, competing indirectly with major players like Medtronic, Gore, Cook Medical, and Endologix. Its direct competition is limited as it offers a novel adjunctive fixation technology rather than a primary graft. However, it must convince clinicians to adopt an added procedural step, competing against the inertia of current practice and any future fixation technologies developed by incumbents.

More companies in Drug Delivery & Formulation →More companies in United States →